Jiri Kaderabek / Shutterstock.com
Increasing numbers of patent challengers are finding the USPTO’s post-grant procedures to be attractive alternatives to district court litigation, write Arlene Chow and Peter Noh.
ore and more pharmaceutical companies are turning to the new US Patent and Trademark Office (USPTO) proceedings available under the America Invents Act (AIA) as a way to attack the validity of bio/pharma patents.
To date, inter partes review (IPR) proceedings, in particular, have been the focal point of post-AIA activity and, according to Patent Trial and Appeal Board (PTAB) statistics dated September 18 this year, 5.6% of IPR petitions relate to bio/pharma patents.
Those petitions are increasing. Over the past five and a half months alone, the number of IPR petitions of bio/pharma patents has almost doubled.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
biotechnology; pharma patents; patents; pharmaceuticals; USPTO; PTAB